No one is happy with the price of drugs nor how we pay for them: not patients, not the lawmakers who represent them, not physicians, not insurance payers and not drug developers. We are at a point ...
With appreciation for feedback from Mark Fendrick, Director of the Value-Based Insurance Design (V-BID) Center at the University of Michigan; Daneen Sekoni, Vice President of Policy and Advocacy at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results